Rebecca E. Chandler

1.4k citations

34 papers · 767 indexed · h-index 14

Co-authors: G. Niklas Norén H. Taavola Karina A. Top Kristina Juhlin Ola Caster I. Ralph Edwards Eyal Muscal Tiphanie P. Vogel
Topics: Pharmacovigilance and Adverse Drug Reactions (16 papers)SARS-CoV-2 and COVID-19 Research (9 papers)Vaccine Coverage and Hesitancy (8 papers)
Cited by: Toxicology Infectious Diseases Health
Journals: Nature reviews. Immunology BMJ Vaccine
Partner nations: Sweden United States United Kingdom

In The Last Decade

Rebecca E. Chandler

30 papers receiving 746 citations

Peers

Countries citing papers authored by Rebecca E. Chandler

Since Specialization

Citations

This map shows the geographic impact of Rebecca E. Chandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca E. Chandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca E. Chandler more than expected).

Fields of papers citing papers by Rebecca E. Chandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca E. Chandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca E. Chandler. The network helps show where Rebecca E. Chandler may publish in the future.

Co-authorship network of co-authors of Rebecca E. Chandler

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca E. Chandler. A scholar is included among the top collaborators of Rebecca E. Chandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca E. Chandler. Rebecca E. Chandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A framework for risk–benefit analysis of vaccines approved through accelerated pathways 2026 ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Simon Cauchemez,Alexander Roberto Precioso,(unknown),Rebecca E. Chandler,(unknown),(unknown),(unknown)	0
2	Systematic Review of Active Safety Surveillance of Vaccines and Medicines in Low- and Middle-Income Countries 2025 ·Drug Safety ·Andy Stergachis,Esperança Sevene,(unknown),Rebecca E. Chandler,Alexander Roberto Precioso,(unknown),Dale Nordenberg,Robert T. Chen	0
3	Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance 2025 ·Drug Safety ·(unknown),Andrew Bate,Jackie Brown,Gianmario Candore,Rebecca E. Chandler,Tarek A. Hammad,Samantha Lane,Judith C. Maro,G. Niklas Norén,Alexandre Pariente,Mulugeta Russom,Maribel Salas,(unknown),Saad Shakir,(unknown),(unknown),Marco Tuccori,Eugène van Puijenbroek,Gianluca Trifirò,(unknown)	3
4	Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally 2024 ·Vaccine X ·(unknown),(unknown),Maria Deloria Knoll,Emmanuelle Espié,Rebecca E. Chandler	7
5	Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future 2023 ·Vaccine ·Steven Black,Rebecca E. Chandler,Kathryn M. Edwards,Miriam Sturkenboom	9
6	The Brighton collaboration standardized module for vaccine benefit-risk assessment 2023 ·Vaccine ·Bennett Levitan,Stephen C. Hadler,William Hurst,Héctor S. Izurieta,Emily Smith,Nicole L. Baker,Vincent Bauchau,Rebecca E. Chandler,Robert T. Chen,(unknown),(unknown),Punnee Pitisuttithum,(unknown),(unknown),(unknown),Sonali Kochhar	5
7	Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets 2022 ·Pharmaceutical Medicine ·Rani Lill Anjum,Rebecca E. Chandler,Elena Rocca	4
8	Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports 2022 ·Drug Safety ·Corine Ekhart,Florence van Hunsel,Eugène van Puijenbroek,Rebecca E. Chandler,(unknown),H. Taavola,G. Niklas Norén	12
9	The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan 2021 ·Drug Safety ·Rika Wakao,Ingrid Lönnstedt,Yasunori Aoki,Rebecca E. Chandler	6
10	Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data 2021 ·Vaccine ·Tiphanie P. Vogel,Karina A. Top,Christos Karatzios,David C. Hilmers,Lorena Tapia,Pamela Moceri,Lisa Giovannini‐Chami,Nicholas Wood,Rebecca E. Chandler,Nicola P. Klein,Elizabeth P. Schlaudecker,M. Cecilia Poli,Eyal Muscal,Flor M. Muñoz	132
11	Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting 2020 ·Drug Safety ·(unknown),(unknown),(unknown),(unknown),Rebecca E. Chandler,H. Taavola,G. Niklas Norén,Rika Wakao	23
12	Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase 2020 ·Drug Safety ·(unknown),H. Taavola,Yasunori Aoki,Rebecca E. Chandler,G. Niklas Norén	37
13	Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence 2020 ·npj Vaccines ·Karsten Juhl Jørgensen,(unknown),Louise Brinth,Rebecca E. Chandler,Peter C Gøtzsche,Tom Jefferson	0
14	The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic 2020 ·Drug Safety ·Rebecca E. Chandler,Deirdre M. McCarthy,Jean-Christophe Delumeau,Mira Harrison‐Woolrych	13
15	Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports 2019 ·Drug Safety ·Rika Wakao,H. Taavola,(unknown),(unknown),(unknown),Rebecca E. Chandler,G. Niklas Norén	32
16	Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events 2019 ·BMJ ·Rebecca E. Chandler	13
17	Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre 2017 ·Drug Safety ·Sarah Watson,Rebecca E. Chandler,H. Taavola,Linda Härmark,Birgitta Grundmark,(unknown),Kristina Star,Florence van Hunsel	36
18	IgA vasculitis (Henoch–Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data 2016 ·Vaccine ·Andreas Woerner,Christoph Rudin,Caterina Bonetto,Carmela Santuccio,Seza Özen,Robert P. Wise,Rebecca E. Chandler,Jan Bonhoeffer	8
19	Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase® 2016 ·Drug Safety ·Rebecca E. Chandler,Kristina Juhlin,(unknown),Ola Caster,I. Ralph Edwards,G. Niklas Norén	70
20	Clostridium difficile-Associated Disease in Oregon: Increasing Incidence and Hospital-Level Risk Factors 2007 ·Infection Control and Hospital Epidemiology ·Rebecca E. Chandler,Katrina Hedberg,Paul R. Cieslak	26

About Rebecca E. Chandler

Rebecca E. Chandler is a scholar working on Toxicology, Health and Infectious Diseases, having authored 34 papers that have together received 767 indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (16 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and Vaccine Coverage and Hesitancy (8 papers). The work is most often cited by research in Toxicology (128 citations), Infectious Diseases (320 citations) and Health (85 citations). Rebecca E. Chandler has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include G. Niklas Norén, H. Taavola, Karina A. Top, Kristina Juhlin, Ola Caster, I. Ralph Edwards, Eyal Muscal, Tiphanie P. Vogel, Katrina Hedberg and David C. Hilmers. Their work appears in journals such as Nature reviews. Immunology, BMJ and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact